Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C

Journal of Medical Virology

Volumn 82, Issue 8, 2010, Pages 1364-1370

  Sanjo, Mai ^a   Saito, Takafumi ^a   Ishii, Rika ^a   Nishise, Yuko ^a   Haga, Hiroaki ^a   Okumoto, Kazuo ^a   Ito, Junitsu ^a   Watanabe, Hisayoshi ^a   Saito, Koji ^a   Togashi, Hitoshi ^b   Fukuda, Kazuto ^c   Imai, Yasuharu ^c   El Shamy, Ahmed ^d   Deng, Lin ^d   Shoji, Ikuo ^d   Hotta, Hak ^d   Kawata, Sumio ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c Ikeda Municipal Hospital   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis C; Interaction; Interferon; Polymorphism; Ribavirin

Indexed keywords

NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; NS3 PROTEIN, HEPATITIS C VIRUS; RECOMBINANT PROTEIN; VIRUS PROTEIN; VIRUS RNA;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS 1B; HUMAN; INFECTION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NUCLEOTIDE SEQUENCE; PATIENT COMPLIANCE; PREDICTION; PROTEIN POLYMORPHISM; PROTEIN SECONDARY STRUCTURE; PRURITUS; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; THYROID DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS ISOLATION; VIRUS LOAD; CHEMISTRY; DNA SEQUENCE; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; MOLECULAR GENETICS; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, SECONDARY; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS; INTERFERON-ALPHA; RECOMBINANT PROTEINS;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1;

EID: 77956594162     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21818     Document Type: Article

References (33)

1. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2006. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 78:83-90. (Pubitemid 41783847)
2. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403-410.
3. Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H. 2005. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 48:138-144. (Pubitemid 41201504)
4. Bruno S, Cammà C, Di Marco V, Rumi M, Vinci M, Camozzi M, Rebucci C, Di Bona D, Colombo M, Craxì A, Mondelli MU, Pinzello G. 2004. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: A randomized controlled trial. J Hepatol 41:474-481.
5. Deng L, Nagano-Fujii M, Tanaka M, Nomura-Takigawa Y, Ikeda M, Kato N, Sada K, Hotta H. 2006. NS3 protein of hepatitis C virus associated with the tumor suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. J Gen Virol 87:1703-1713. (Pubitemid 43827226)
6. El-Shamy A, Sasayama M, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. 2007. Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pretreatment sera. Microbiol Immunol 51:471-482.
7. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. 2008. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48:38-47.
8. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81. (Pubitemid 26017933)
9. Evans JD, Seeger C. 2006. Cardif: A protein central to innate immunity is inactivated by the HCV NS3 serine protease. Hepatology 43:615-617.
10. Foy E, Li K, Wang C, Sumpter R, Jr., Ikeda M, Lemon SM, Gale M, Jr. 2003. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300:1145-1148.
11. Gale MJ, Jr., Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG. 1997. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230:217-227.
12. Gale MJ, Jr., Korth MJ, Katze MG. 1998. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: A potential mechanism of interferon resistance. Clin Diagn Virol 10:157-162.
13. Garnier J, Osguthorfe DJ, Robson B. 1978. Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. J Mol Biol 120:97-120.
14. Grandvaux N, Servant MJ, tenOever B, Sen GC, Balachandran S, Barber GN, Lin R, Hiscott J. 2002. Transcriptional profiling of interferon regulatory factor 3 target genes: Direct involvement in the regulation of interferon-stimulated genes. J Virol 76:5532-5539.
15. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355.
16. Hiramatsu N, Kurashige N, Oze T, Takehara T, Tamura S, Kasahara A, Oshita M, Katayama K, Yoshihara H, Imai Y, Kato M, Kawata S, Tsubouchi H, Kumada H, Okanoue T, Kakumu S, Hayashi N. 2008. Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C. Hepatol Res 38:52-59.
17. Ishido S, Hotta H. 1998. Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. FEBS Lett 438:258-262. (Pubitemid 28529285)
18. Kwun HJ, Jung EY, Ahn JY, Lee MN, Jang KL. 2001. p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J Gen Virol 82:2235-2241.
19. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 358:958-965. (Pubitemid 32913521)
20. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167-1172.
21. Murphy MD, Rosen HR, Marousek GI, Chou S. 2002. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci 47:1195-1205.
22. Nakaya T, Sato M, Hata N, Asagiri M, Suemori H, Noguchi S, Tanaka N, Taniguchi T. 2001. Gene induction pathways mediated by distinct IRFs during viral infection. Biochem Biophys Res Commun 283:1150-1156.
23. Nishise Y, Saito T, Sugahara K, Ito JI, Saito K, Togashi H, Nagano-Fujii M, Hotta H, Kawata S. 2007. Risk of hepatocellular carcinoma and secondary structure of hepatitis C virus (HCV) NS3 protein amino-terminus, in patients infected with HCV subtype 1b. J Infect Dis 196:1006-1009.
24. Nousbaum J, Polyak SJ, Ray SC, Sullivan DG, Larson AM, Carithers RL, Jr., Gretch DR. 2000. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 74:9028-9038.
25. Ogata S, Ku Y, Yoon S, Makino S, Nagano-Fujii M, Hotta H. 2002a. Correlation between secondary structure of an amino-terminal portion of the nonstructural protein 3 (NS3) of hepatitis C virus and development of hepatocellular carcinoma. Microbiol Immunol 46:549-554. (Pubitemid 34947853)
26. Ogata S, Nagano-Fujii M, Ku Y, Yoon S, Hotta H. 2002b. Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma. J Clin Microbiol 40:3625-3630.
27. Ogata S, Florese RH, Nagano-Fujii M, Hidajat R, Deng L, Ku Y, Yoon S, Saito T, Kawata S, Hotta H. 2003. Identification of hepatitis C virus (HCV) subtype 1b strains that are highly, or only weakly, associated with hepatocellular carcinoma on the basis of the secondary structure of an amino-terminal portion of the HCV NS3 protein. J Clin Microbiol 41:2835-2841.
28. Pearlman BL. 2004. Hepatitis C treatment update. Am J Med 117:344-352.
29. Puig-Basagoiti F, Forns X, Furcić I, Ampurdanés S, Giménez-Barcons M, Franco S, Sánchez-Tapias JM, Saiz JC. 2005. Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J Gen Virol 86:1067-1075.
30. Sakamuro D, Furukawa T, Takegami T. 1995. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 69: 3893-3896.
31. Sarrazin C, Herrmann E, Bruch K, Zeuzem S. 2002. Hepatitis C virus nonstructural 5A protein and interferon resistance: A new model for testing the reliability of mutational analyses. J Virol 76:11079-11090. (Pubitemid 35176224)
32. Yamada K, Mori A, Seki M, Kimura J, Yuasa S, Matsuura Y, Miyamura T. 1998. Critical point mutations for hepatitis C virus NS3 proteinase. Virology 246:104-112.
33. Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T. 2008. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: Impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig 28:9-16.